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ABSTRACT
Background: High miR-31-3p expression is associated with inferior outcomes 
in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-
EGFR therapy. This study evaluated miR-31-3p expression in patients with operable 
colorectal liver metastases (LM) enrolled in the New EPOC study.
Methods: MiR-31-3p expression was measured in primary tumors (PT) from 149 
KRAS WT patients including 71 receiving chemotherapy alone (CT) and 78 receiving 
chemotherapy plus cetuximab (CTX). Each treatment arm was split into tertiles based 
on miR-31-3p expression levels. MiR-31-3p expression was also measured in LM from 
94 patients with tumor tissue available.
Results: The median progression-free survival for the combined populations with 
mid or high miR-31-3p expression was shorter in the CTX versus the CT arm (26.7 
months versus 12.3 months, HR=2.28 95%CI 1.27; 4.09 p=0.006). Low miR-31-3p 
expressers had similar outcomes irrespective of treatment (HR=1.06 95%CI 0.43; 
2.61 p=0.9). MiR-31-3p expression was correlated between paired PT and LM samples 
in the CT group but not in the CTX group.
Conclusions: Patients with low miR-31-3p expression in the New EPOC study were 
not harmed by the addition of cetuximab. This supports miR-31-3p as a promising 
predictive biomarker for anti-EGFR therapy in KRAS WT advanced colorectal cancer.
INTRODUCTION
There have been significant improvements in the 
management of colorectal cancer over the last decade 
involving increasingly sophisticated combinations of 
chemotherapy, targeted agents, and surgery. This has 
included the use of anti-epidermal growth factor receptor 
(EGFR) antibodies such as cetuximab. Following several 
studies demonstrating the benefit of cetuximab as a 
single agent or in combination with chemotherapy for 
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advanced colorectal cancer, [1-4] its role was evaluated 
as an adjunct to chemotherapy and surgery for operable 
colorectal liver metastases in the New EPOC study. [5] 
Unexpectedly, this resulted in a shorter progression-free 
survival for patients treated with cetuximab in contrast to 
previous data associated with its use in inoperable disease. 
This effect persisted despite restriction of patients to an 
all RAS subgroup, suggesting that additional biomarkers 
linked with treatment efficacy have yet to be identified [6].
MicroRNAs (miRNA) are small non-coding RNA 
molecules that play a key role in the regulation of intracellular 
processes through post-transcriptional regulation of gene 
expression. The stable presence of miRNAs in formalin-fixed 
paraffin-embedded (FFPE) tissues and their involvement in 
multiple physiological pathways and pathologies suggests an 
opportunity to identify new biomarkers for multiple diseases. 
[7-11] MicroRNAs controlling expression of oncogenes and 
tumor suppressor genes have been shown to be frequently 
deregulated in cancer cells [7-9] suggesting potential 
biomarker candidates for precision oncology.
A miRNA which has both oncogenic and tumor 
suppressive functional roles frequently deregulated in 
a variety of cancers is mir-31. [12] In colorectal cancer, 
mir-31 is typically overexpressed with high expression 
correlating with advanced disease. [13-15] Functional 
studies have shown mir-31 has pleiotropic activity, 
promoting colorectal cancer progression through enhanced 
migration and invasion. [16, 17] While the most frequently 
identified mature sequence of mir-31 identified in the 
literature is miR-31-5p, the other mature sequence of mir-
31, miR-31-3p, has been reported to be associated with 
outcomes for patients treated with anti-EGFR therapy. 
[18-20] As a follow-up to these findings, the present study 
sought to evaluate whether expression of miR-31-3p could 
predict outcomes in the setting of operable colorectal liver 
metastasis in patients treated with chemotherapy plus 
cetuximab enrolled in the New EPOC study.
RESULTS
The modified ITT population (mITT) was composed 
of 149 patients, 78 patients in a chemotherapy plus 
cetuximab arm and 71 patients in a chemotherapy alone 
arm (Figure 1). One hundred and thirteen of these patients 
were confirmed all RAS WT. Thirty-six patients in the 
mITT population had incomplete RAS mutational status 
by NGS but were known to be KRAS WT (codons 12, 13, 
and 61) based on pyrosequencing results obtained during 
the original New EPOC study.
Patient baseline characteristics in mITT and 
association with miR-31-3p expression
In the mITT population, baseline characteristics 
were well balanced between treatment arms (Table 1) and 
between miR-31-3p expression tertiles (Table 2) with the 
exception of BRAF mutational status, which was more 
frequent in the high tertile group (6/7 BRAF mutations were 
in patients with high miR-31-3p expression, p=0.017).
Patient clinical outcomes in mITT population
Despite a high percentage of censored patients (52% 
for progression-free survival and 82% for overall survival) 
progression-free survival was significantly shorter in the 
chemotherapy plus cetuximab arm versus the chemotherapy 
alone arm with a median of 14.5 months versus 24.2 months 
(HR=1.8 [1.1 ; 2.9], p=0.02). The same was observed for 
overall survival (HR=2.2 [1.0 ; 4.9], p=0.047). The above 
aligns with previously published results from the New 
EPOC interim analysis. [20]
miR-31-3p as a prognostic marker in patients 
treated with chemotherapy plus cetuximab
Progression-free survival was not significantly 
different between the miR-31-3p expression subgroups 
in the whole mITT population (Figure 2A) with a 
median progression free survival of 18.0 months in the 
low expression subgroup versus 15.9 months in the 
combined mid plus high expression subgroup (HR=1.4 
[0.8 ; 2.3] p=0.25). In the chemotherapy alone arm 
(Figure 2B), progression-free survival was not statistically 
different between the miR-31-3p expression subgroups 
(HR=0.9 [0.4 ; 2.0], p=0.79). In contrast, patients in 
the chemotherapy plus cetuximab arm (Figure 2C) with 
low miR-31-3p expression had a longer progression-
free survival compared to patients in the combined mid 
plus high expression subgroup (median of 20.3 months 
versus 12.3 months, HR=2.0 [1.0 ; 4.2], p=0.049). Overall 
survival was not significantly different between the miR-
31-3p expression groups in the whole mITT population 
(HR=0.9 [0.4 ; 2.1], p=0.86), in the chemotherapy alone 
arm (HR=0.7 [0.2 ; 2.9], p=0.62), or in the chemotherapy 
plus cetuximab arm (HR=1.1 [0.4 ; 3.0], p=0.85).
Objective response rates did not significantly vary 
according to miR-31-3p expression in the whole mITT 
population with 34 patients (68%) achieving complete or 
partial response out of the 50 patients with low miR-31-3p 
expression and 62 patients (63%) out of the 99 in the mid plus 
high miR-31-3p expression subgroup, (p=0.59). There was 
also no difference in objective response rate when analyzed 
by treatment arm. For the chemotherapy alone arm, 15 of 
the 23 patients (65%) with low miR-31-3p expression and 
27 of the 48 patients (56%) in the mid plus high miR-31-3p 
expression subgroup achieved complete or partial responses 
(p=0.61). For the chemotherapy plus cetuximab arm, 19 of 
the 27 patients (70%) with low miR-31-3p expression and 35 
of the 51 (69%) with mid or high miR-31-3p expression had 
a complete or partial response (p=1.0).
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miR-31-3p as predictive marker of cetuximab 
efficacy on survival outcomes
Patients in the mid plus high miR-31-3p expression 
group treated with cetuximab had a shorter progression free 
survival compared to patients treated with chemotherapy 
alone (median progression free survival 12.3 versus 26.7 
months respectively; HR=2.3 [1.3 ; 4.1], p=0.005). This 
difference was not observed in low expressers (median 
progression free survival 20.3 months versus 18.9 months 
respectively; HR=1.1 [0.4 ; 2.6] p=0.91) (Figure 3). Patients 
in the mid plus high miR-31-3p expression group treated 
with cetuximab also had a non-significantly shorter overall 
survival compared to patients treated with chemotherapy 
alone (HR=2.5 [0.9; 6.5], p=0.06). This difference was not 
observed in low expressers (HR=1.6 [0.4 ; 6.7] p=0.49) 
(Figure 4). The treatment-miR-31-3p expression group 
interaction test was not significant (p=0.16).
Objective response rates were not significantly 
different according to treatment arm. For the mid plus 
high miR-31-3p expression subgroup, 35 of the 51 patients 
(68%) in the chemotherapy plus cetuximab arm, and 27 
of the 48 patients (56%) in the chemotherapy alone arm 
achieved either a partial or complete response; p=0.22. For 
the low expressers subgroup, 19 of the 27 patients (70%) 
in the chemotherapy plus cetuximab arm and 15 of the 23 
patients (65%) in the chemotherapy alone arm achieved 
either a partial or complete response; p=0.77.
Multivariate analyses
Consistent with the univariate analysis results, 
multivariate analyses adjusted for confounding factors 
showed that miR-31-3p expression group was not a 
significant predictive factor for progression free survival 
in the overall population or in the chemotherapy alone 
arm, but remained significant in the cetuximab treated 
population (low versus mid-high, HR = 2.1 [1.0; 4.4], 
p=0.05).
Comparison of miR-31-3p expression between 
metastases and primary tumors
An analysis of miR-31-3p expression in liver 
metastases collected post neoadjuvant treatment versus 
primary tumors collected at baseline was performed using 
94 paired samples of primary tumors and liver metastases. 
MiR-31-3p expression was significantly lower in metastases 
compared to primary tumors with a mean (std) of log-fold of 
-0.66 (1.18) for primary tumors versus -1.79 (1.37) for liver 
metastases, p<0.001. Expression levels did not significantly 
differ between treatment arms either in primary tumors 
(-0.81 [1.11] for chemotherapy plus cetuximab versus 
-0.87 [1.18] for chemotherapy alone, p=0.45) or in liver 
metastases (-1.68 [1.28] for chemotherapy plus cetuximab 
versus -1.96 [1.43] for chemotherapy alone, p=0.76). The 
absolute change of expression between treatment arms was 
Figure 1: Flow diagram for patients included in study.
Oncotarget93859www.impactjournals.com/oncotarget
not significantly different (0.87 [1.32] for chemotherapy 
plus cetuximab versus 1.08 [1.62] for chemotherapy alone, 
p=0.36) (Figure 5).
In the 47 paired samples from the chemotherapy 
alone arm, miR-31-3p expression levels in primary tumors 
and corresponding metastases were highly correlated with a 
correlation coefficient of 0.42; p=0.0031. In contrast, for the 
47 paired samples from the chemotherapy plus cetuximab arm, 
a lower, non-statistically significant correlation was observed 
(correlation coefficient = 0.22, p=0.14) (Figure 6A and 6B).






F 25 (35.2%) 22 (28.2%)
M 46 (64.8%) 56 (71.8%)
Age
[0-60] 20 (28.2%) 19 (24.4%)
[60-70] 34 (47.9%) 39 (50%)
[70+] 17 (23.9%) 20 (25.6%)
Chemotherapy regimen
CapOx 15 (21.4%) 18 (23.4%)
FOLFIRI 6 (8.6%) 12 (15.6%)
FOLFOX 49 (70%) 47 (61%)
BRAF status
WT/Unknown 68 (95.8%) 73 (94.8%)
Mutated 3 (4.2%) 4 (5.2%)
Primary tumor location
Left sided 59 (83.1%) 59 (75.6%)
Right sided 12 (16.9%) 19 (24.4%)
Presentation of metastases
Non-synchronous 33 (46.5%) 24 (30.8%)
Synchronous 38 (53.5%) 54 (69.2%)
Number of liver metastases
< 4 57 (81.4%) 58 (74.4%)
≥ 4 13 (18.6%) 20 (25.6%)
ECOG performance status
0 51 (71.8%) 54 (69.2%)
1 20 (28.2%) 22 (28.2%)
2 0 (0%) 2 (2.6%)
miR tertiles
Low 23 (32.4%) 27 (34.6%)
Intermediate 20 (28.2%) 29 (37.2%)
High 28 (39.4%) 22 (28.2%)
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Table 2: Baseline characteristics in the mITT population for each miR-31-3p tertile
Low n = 50 Intermediate n = 49 High n = 50 p-value
Sex
F 13 (26%) 19 (38.8%) 15 (30%)
0.401
M 37 (74%) 30 (61.2%) 35 (70%)
Age
[0-60] 11 (22%) 12 (24.5%) 16 (32%)
0.815[60-70] 27 (54%) 24 (49%) 22 (44%)
[70+] 12 (24%) 13 (26.5%) 12 (24%)
Chemotherapy regimen
CapOx 10 (20.4%) 10 (20.4%) 13 (26.5%)
0.439FOLFIRI 3 (6.1%) 8 (16.3%) 7 (14.3%)
FOLFOX 36 (73.5%) 31 (63.3%) 29 (59.2%)
BRAF status
WT/Unknown 49 (98%) 48 (100%) 44 (88%)
0.017
Mutated 1 (2%) 0 (0%) 6 (12%)
Primary tumor location
Left+rectum 43 (86%) 39 (79.6%) 36 (72%)
0.229
Right 7 (14%) 10 (20.4%) 14 (28%)
Presentation of metastases
Non-synchronous 18 (36%) 19 (38.8%) 20 (40%)
0.933
Synchronous 32 (64%) 30 (61.2%) 30 (60%)
Number of liver metastases
< 4 37 (75.5%) 38 (77.6%) 40 (80%)
0.855
≥ 4 12 (24.5%) 11 (22.5%) 10 (20%)
ECOG performance status
0 34 (68%) 34 (69.4%) 37 (74%)
0.8501 15 (30%) 15 (30.6%) 12 (24%)
2 1 (2%) 0 (0%) 1 (2%)
Figure 2: Kaplan-Meier curves of progression-free survival (PFS) according to miR-31-3p expression level groups. 




The New EPOC study demonstrated a shorter 
progression-free survival with the addition of cetuximab 
to chemotherapy for patients with operable colorectal liver 
metastases. [5] While it is a reminder that the consequences 
of combining treatment strategies can be unpredictable, 
it does afford a unique opportunity to increase our 
understanding of tumor responses to treatment with anti-
EGFR therapy. Not only can putative predictive biomarkers 
be assessed in the “pre-treatment” primary tumor tissue, but 
the additional availability of “post-treatment” resected liver 
metastases enables paired analyses to aid a mechanistic 
dissection of the effect of cetuximab.
In our study we observed that in the subgroup of 
patients treated with cetuximab, patients in the combined 
mid plus high miR-31-3p expression group had a shorter 
progression free survival in comparison to patients treated 
Figure 3: Kaplan-Meier curves of progression-free survival (PFS) by treatment arm. (A) OS for the mid plus high miR-31-
3p expressers; (B) OS for low miR-31-3p expressers.
Figure 4: Kaplan-Meier curves of overall survival (OS) by treatment arm. (A) OS for the mid plus high miR-31-3p expressers; 
(B) OS for low miR-31-3p expressers.
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Figure 5: Distribution of miR-31-3p expression (logarithmic scale) by treatment arm, in primary tumor and liver 
metastases. (CT = chemotherapy alone treatment arm; CTX = chemotherapy + chemotherapy treatment arm).
Figure 6: Correlation of miR-31-3p expression (log-transformed) between paired primary tumors and liver metastases (A) chemotherapy 
alone treatment arm; (B) chemotherapy + cetuximab treatment arm.
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with low miR-31-3p expression. By contrast in the 
chemotherapy alone arm, progression free survival was 
similar regardless of miR-31-3p expression level. We also 
observed that patients in the mid plus high miR-31-3p 
expression group had a shorter progression free survival 
and shorter overall survival when treated with cetuximab 
compared to patients treated with chemotherapy alone, 
whereas patients with low miR-31-3p expression had 
similar clinical outcomes for both study treatment arms.
Although we could not demonstrate the predictivity of 
miR-31-3p (homogeneity test p-value p=0.16), this is likely 
due to the low number of patients and lack of maturity of the 
data (52% censored patients for progression free survival 
and 82% for overall survival). The power of this study to 
demonstrate predictivity, computed a posteriori, was only 
65.3%. [21] Similarly, the absence of demonstration of a 
prognostic effect of miR-31-3p on overall survival in the 
cetuximab-treated population is likely to be related to the 
limited number of events.
We failed to observe a clear association between 
miR-31-3p expression and response to cetuximab. 
This could be due to several reasons including the 
high objective response rate observed both in the 
chemotherapy alone (42/71 59%) and cetuximab (54/78 
69%) arms suggesting that cetuximab impact on the tumor 
response was relatively marginal, limiting the capacity to 
demonstrate an interaction between miR-31-3p expression 
and response in this setting.
While analysis of miR-31-3p expression and its 
association to clinical outcomes did not enable the ability 
to identify a patient subgroup that benefited from the 
addition of cetuximab to chemotherapy, this needs to be 
interpreted in the context of the results of the New EPOC 
study in which the addition of cetuximab to chemotherapy 
produced a detrimental effect. However, our results show 
that the poorer outcomes associated with the addition of 
cetuximab to chemotherapy were limited to patients who 
had middle to high miR-31-3p expression and that this 
detrimental effect was not observed in patients with low 
miR-31-3p expression levels. As such, the predictive value 
of miR-31-3p expression is consistent with the primary 
outcome of the New EPOC study.
The potential interest of miR-31-3p expression as a 
predictive biomarker of the response to anti-EGFR therapy 
in metastatic colorectal cancer has been previously reported 
in several papers. [19, 20] Preliminary results of studies 
assessing the association with miR-31-3p expression and 
therapeutic benefit from anti-EGFR therapy have also been 
reported for the PICCOLO and FIRE-3 studies. [22, 23] The 
present analysis was performed prior to the determination 
of the optimal cut-off value for miR-31-3p that has recently 
been reported based on the analysis of tumors samples from 
patients enrolled in the FIRE-3 trial. [23] As a result, the 
present study in which the patient population was separated 
into tertiles represents an initial exploration of potential cut-
off points for miR-31-3p expression as it relates to differential 
outcomes. Although the specific context and results of the 
study as well as the lack of maturity of the data, prevent the 
generalization of the conclusions to other clinical settings, we 
believe the present study contributes to the accumulation of 
data supporting the clinical and biological rationale of miR-
31-3p expression as a predictive biomarker of response to 
anti-EGFR therapy in metastatic colorectal cancer.
The loss of correlation of miR-31-3p expression 
level for the cetuximab group between primary tumors, 
which were collected prior to any treatment, and liver 
metastasis, which were collected after treatment, suggests 
that treatment with cetuximab may alter the expression of 
this microRNA. This finding suggests the regulation of 
miR-31-3p expression as a part of the EGFR pathway and 
is consistent with a previous report where maturation of 
mir31 in the miR-31-5p form was found to be regulated 
via EGFR in a tumor hypoxia context. [24] It is also 
important to note that the selection of miR-31-3p for the 
present study was done following a broad screening of 
1,145 miRNAs, [19] and as a result of previous findings 
that pre-mir-31 leads to maturation of the highly correlated 
mature forms of mir-31, miR-31-3p and miR-31-5p. [20] 
Despite this high correlation between the two mature 
forms of mir-31, prediction of response to anti-EGFR 
therapy differs between miR-31-3p and miR-31-5p, 
suggesting the existence of fine regulation mechanisms 
involving specifically miR-31-3p or genes targeted by 
miR-31-3p, beyond regulation of mir-31 expression. [18]
In summary, analysis of miR-31-3p expression 
enabled the identification of a subgroup of patients with 
operable colorectal liver metastases who have a poorer 
outcome when treated with chemotherapy plus cetuximab. 
While the mechanism of this differential effect relative to 
miR-31-3p expression requires investigation, these data 
support a biological explanation for the detrimental effect 
observed with the use of cetuximab in patients in the New 
EPOC study, rather than, for example, inadequate surgery 
being responsible. Further work is ongoing to validate the 




The New EPOC trial has previously been reported 
[5] and the full protocol can be found on the Southampton 
Clinical Trials Unit website (www.ctu.soton.ac.uk). Patients 
with resectable or suboptimally resectable liver metastases 
from colorectal cancer were randomly allocated to two 
treatment arms; chemotherapy (oxaliplatin/irinotecan plus 
fluorouracil) with or without cetuximab given before and 
after liver resection. The study was closed by the Trial 
Steering Committee on advice from the Data Monitoring 
and Ethics Committee (DMEC) in November 2012 when 
the protocol defined futility criteria were met (the lower 
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limit of the 95% Confidence Interval (CI) for progression 
free survival HR was >1). [25]
Primary tumor and liver metastasis samples 
collected from patients enrolled in the New EPOC trial 
were analyzed for the present study. As per the New 
EPOC study protocol, primary tumor samples were 
collected at baseline and samples for liver metastases 
were collected following neoadjuvant treatment and liver 
resection. Primary tumors from 167 of the 236 patients 
in the original primary analysis population [5] were 
available for extended RAS mutational testing and miR-
31-3p expression in the current analysis. The modified 
intention to treat (mITT) population was defined as those 
patients included in the original New EPOC primary 
analysis population (e.g. those who were KRAS wild-type 
for codons 12, 13 and 61 at trial entry) in whom further 
testing did not demonstrate any RAS mutation. This 
resulted in a mITT population comprised of 149 patients. 
Liver metastasis samples were available for 147 patients 
enrolled in the original New EPOC study with paired 
samples of both primary tumor and metastasis available 
for a total of 94 included in the mITT population.
Mutational analyses
Primary tumors and metastases analyzed for the 
present study were sequenced for KRAS codons 12, 13, 
61, 117 and 146, NRAS codons 12, 13, 61, 117 146, and 
BRAF codon 600 using Sequencing By Synthesis (SBS) 
on a MiSeq platform (Illumina, San Diego, California). 
Mutations were identified with respect to two known 
non-mutated controls for all mutations considered and the 
three positions of the codon were analyzed when needed. 
A 99% confidence interval for the minor allele frequency 
was calculated, taking into account the total number of 
bases read for a nucleotide in a particular codon and the 
number of “new” bases read for the same nucleotide 
of the same codon. Mutations were considered actual 
results when the same base was identified regarding the 
2 controls. A frequency below 5% was considered as non-
mutated. Samples which had indeterminate results were 
resequenced using Ion TorrentTM Technology (Thermo 
Fisher Scientific, Carlsbad, CA). For this analysis libraries 
were prepared according the manufacturer’s instruction 
(Ion AmpliSeqTM DNA and RNA Library Preparation 
Rev.B, Ion Torrent, Thermo Fisher Scientific, Carlsbad, 
CA). Samples were amplified with the Ion AmpliSeq TM 
Cancer HotSpot Panel v2 and the concentration of each 
library was determined with ExperionTM Automated 
Electrophoresis system (Bio-Rad Laboratories Inc., 
Hercules, CA). Emulsion PCR was done according to 
the manufacturer’s user guide (Ion PGMTM Template 
OT2 200 Kit Revision A.0). Sequencing was performed 
using two Ion 318TM Chip V2 on an Ion PGM SystemTM. 
Data analysis, including alignment to the hg19 human 
reference genome and variant calling, was done using the 
Torrent Suite Software v4.0. Alignments were visually 
verified and annotated with the ALAMUT software v2.2 
(Interactive Biosoftware, Rouen, France).
MiR-31-3p expression analyses
A pathologist reviewed all samples and the tumor 
area was marked for subsequent macrodissection. Only 
samples with more than 20% tumor cell content were 
selected for nucleic acid extraction. For each tumor 
sample, 5 FFPE slides of 5μm thickness were scratched 
in the tumor area and total RNA was extracted using the 
FFPE miRNeasy extraction kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. Specific 
quantification of expression level of miRNA hsa-miR-31-
3p was performed on retrotranscribed RNA using specific 
TaqMan pre-designed assays on ABI7900HT Real-Time 
PCR System. Expression levels were normalized to a 
reference miRNA using the ΔΔCt method.
Statistical analysis
The primary endpoint was progression free survival 
defined as the time from randomization to recurrence, 
disease progression, or death, whichever occurred first. 
Secondary endpoints included overall survival (time from 
randomization to death; patients still alive at the date of 
last follow-up were censored) and preoperative response 
(using Response Evaluation Criteria in Solid Tumors 
(RECIST) version 1.0). All analyses reported here include 
data up to November 1, 2012 to match the time frame 
presented in the interim report to the DMEC.
Analyses were performed for the modified Intent-
to-Treat (mITT) population which consisted of 149 
KRAS WT patients whose RAS status was either WT or 
indeterminate. Patients whose tumors were confirmed 
to be KRAS or RAS mutated were excluded from the 
analysis. In line with the study’s pre-specified statistical 
analysis plan, patients were divided into three subgroups 
defined as either low, medium (mid) or high miR-31-3p 
expression levels based on tertiles of miR-31-3p expression 
distribution. Progression free survival and overall survival 
comparisons according to miR-31-3p expression tertile 
and between each treatment arm were performed using 
Kaplan-Meier (KM) methodology and two-sided log-rank 
test. Objective Response Rate according to tertiles and 
across treatment arms were compared using Fisher exact 
test, considering non-evaluable patients as non-responders. 
Because similar results were observed in the mid and 
high tertile subgroups (Supplementary Figure 1), these 
subgroups were merged into a single “high” miR-31-3p 
expression subgroup and subsequent analyses compared the 
“low” miR-31-3p expression subgroup (low tertile) with the 
“high” subgroup (mid + high tertiles). Impact of covariates 
on progression free survival or overall survival (i.e. age, 
gender, ECOG status, tumor location, BRAF mutational 
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status, chemotherapy backbone, number of liver metastases) 
was first analyzed in separate univariate Cox models and 
then in a multivariate stepwise Cox model. Potential 
predictors with univariate p-value below 0.20 were selected 
to enter in the model and were kept in the multivariate 
model if their multivariate p-value was below 0.10. MiR-
31-3p predictivity was explored in this multivariate model 
using an interaction term of treatment with miR-31-3p 
subgroup. Expression levels of miR-31-3p in LM vs PT 
were compared using the log of miR-31-3p expression fold 
and a paired Student t test. A Pearson test was performed 
to evaluate correlation of miR-31-3p expression in primary 
tumors and their paired liver metastases. Two-way analysis 
of variance was used to test paired primary tumor-liver 
metastases and treatment effects on miR-31-3p expression.
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